North America was the largest region in the oncology drugs market in 2016, accounting for 31% market share. Asia Pacific was the second largest region accounting for around 24% market share. Western Europe was the smallest region accounting for around 22% market share.
Oncology Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the oncology drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the oncology drugs market and suggests approaches.
Reasons to Purchase
• Get up to date information available on the oncology drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
Markets Covered: Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Kidney Cancer, Gastric Cancer, Brain Tumor, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Bladder Cancer, Thyroid Cancer, Others.
Companies Mentioned: F. Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences, Inc., Bayer AG, Takeda Pharmaceuticals, Johnson & Johnson, Pfizer Inc., Boehringer Ingelheim GmbH, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd.
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others.
Table of Contents
The global oncology drugs market is expected to reach around $150 billion in 2020. The oncology drugs market is expected to grow due to the increasing number of expensive but advanced and effective medications that will help in increasing the life expectancy of cancer patients. For example, in 2017, Kite Pharma’s CAT-T cell therapy, under clinical trial, showed results of increased life expectancy of terminally ill lymphoma patients by 9 months after a single treatment.
Collaboration Driving Innovation - Companies in the oncology drug market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive oncology drug market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by striking partnering, in or out licensing deals, this trend may have increased in recent years. For instance, in January 2016, AstraZeneca and Moderna Therapeutics entered into a collaboration to discover, co-develop and co-commercialize immuno-oncology mRNA therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology. Servier and Novartis have also extended their collaboration to co-develop and commercialize anti-Mcl-1 drug candidates for cancer treatment.
Oncology Drugs Market Characteristics 5
Get Customized Report
Oncology Drugs Market Historic Growth 7
Oncology Drugs Market Forecast Growth 8
Oncology Drugs Market Segmentation 9
Global Oncology Drugs Market, Split By Segments, 2016, $ Billion 9
Blood Cancer 10
Breast Cancer 10
Cervical Cancer 11
Lung Cancer 11
Colorectal Cancer 11
Non-Small Cell Lung Cancer 11
Prostate Cancer 11
Kidney Cancer 11
Gastric Cancer 11
Brain Tumor 11
Pancreatic Cancer 11
Skin Cancer 11
Ovarian Cancer 11
Bladder Cancer 11
Thyroid Cancer 11
Global Oncology Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 12
Oncology Drugs Market Geography Regional and Country Comparison 14
Global Oncology Drugs Market, Split By Regions, 2016 14
Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 16
Global Oncology Drugs Market, Split By Country, 2016 18
Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 20
Oncology Drugs Market Competitive Landscape 22
F. Hoffmann-La Roche Ltd. 23
Novartis AG 23
Gilead Sciences, Inc. 23
Bayer AG 23
Takeda Pharmaceuticals 23
Johnson & Johnson 23
Otsuka Pharmaceutical Co., Ltd. 23
Boehringer Ingelheim GmbH 23
Eli Lilly And Company 23
Pfizer Inc. 23
F.Hoffmann-La Roche 24
Gilead Sciences, Inc. 25
Oncology Drugs Market Key Mergers And Acquisitions 26
Novartis Acquired GSK’s Oncology 26
Pfizer Acquired Medivation 26
Takeda Pharmaceutical Company Acquires ARIAD Pharmaceuticals, Inc. 26
Roche Acquired Seragon 26
Jazz Pharmaceuticals Acquired Celator 26
Sumitomo Dainippon Pharma Co. Ltd. Acquires Tolero Pharmaceuticals 26
Ipsen Acquires Oncology Assets From Merrimack Pharmaceuticals 26
Celldex Therapeutics Acquires Kolltan Pharmaceuticals 27
Merck Acquired OncoEthix 27
NeoGenomics Acquired Clarient 27
Merger Of Threshold Pharmaceuticals With Molecular Templates, Inc. 27
Definitive Merger Of Achieve Life Science, Inc. By OncoGenex Pharmaceuticals, Inc. 27
Oncology Drugs Market Trends And Strategies 28
Collaboration Driving Innovation 28
Biomarker Driven R&D 28
Increasing Demand For Personalized Medicines 28
NAICS Definitions Of Industry Covered In This Report 30
Definition Of Market Covered In This Report 30
Research Methodology 31
Research Inquiries 32
The Business Research Company 32
List of Figures
Figure 1: Global Oncology Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Figure 2: Global Oncology Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Figure 3: Global Oncology Drugs Market, Split By Segments, 2016, $ Billion 9
Figure 4: Global Oncology Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 12
Figure 5: Global Oncology Drugs Market, Split By Region, 2016, $ Billion 14
Figure 6: Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 16
Figure 7: Global Oncology Drugs Market, Split By Country, 2016, $ Billion 18
Figure 8: Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 20
Figure 9: Global Oncology Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 22
List of Tables
Table 1: Global Oncology Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Table 2: Global Oncology Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Table 3: Global Oncology Drugs Market, Split By Segments, 2016, $ Billion 10
Table 4: Global Oncology Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 13
Table 5: Global Oncology Drugs Market, Split By Region, 2016, $ Billion 15
Table 6: Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 16
Table 7: Global Oncology Drugs Market, Split By Country, 2016, $ Billion 18
Table 8: Global Oncology Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 20
Table 9: Global Oncology Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 23
Please fill in your details. Our team will get back to you